These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 15049885

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [Abstract] [Full Text] [Related]

  • 23. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD.
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [Abstract] [Full Text] [Related]

  • 24. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators.
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM.
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [Abstract] [Full Text] [Related]

  • 28. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 29. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women.
    Hirsch LJ, Pryor-Tillotson S.
    Ann Ital Med Int; 1995 Oct; 10 Suppl():22S-28S. PubMed ID: 8562261
    [Abstract] [Full Text] [Related]

  • 38. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD.
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [Abstract] [Full Text] [Related]

  • 39. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 40. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T.
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.